Gyala Therapeutics

Name

Gyala Therapeutics

Legal name

Gyala Therapeutics SL

Website

https://gyalatx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

CAR-T Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Developers (Autologous) (HLAAABAA), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• CAR-T cell therapy
• Cancer immunotherapy
• Hematologic malignancies
• Cell therapy development
• Acute leukemia treatment

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. CAR-T Cell Therapy Development and Commercialization: Pre-revenue clinical stage company developing CAR-T cell therapy GYA01 for treatment of acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL). The company is currently conducting Phase I/IIa clinical trials and has no commercialized products. Revenue generation would likely come from eventual therapy commercialization, licensing, or partnership agreements.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Gyala Therapeutics is developing GYA01, a first-in-class autologous CAR-T cell therapy in which a patient's T lymphocytes are genetically modified to express a chimeric antigen receptor that targets the CD84 protein overexpressed on acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL) cells. The investigational therapy is administered through a Phase I/IIa clinical trial with decentralized GMP manufacturing at Hospital La Fe (Valencia) and Hospital Clínic Barcelona under AEMPS authorization.

Product overview

Gyala Therapeutics is a clinical-stage biotechnology company developing a single core product, GYA01, a first-in-class CAR-T cell therapy. GYA01 targets the CD84 protein and is designed for acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), representing a first-in-class therapy for these hematologic malignancies with no currently approved CAR-T options. The company is currently conducting a Phase I/IIa clinical trial at Hospital La Fe in Valencia and Hospital Clínic Barcelona.

Differentiator

Problem solved

Functional benefit

Products and services

• GYA01 (CAR-T cell therapy) Investigational, first-in-class autologous CAR-T cell therapy in which a patient's T lymphocytes are genetically modified to express a chimeric antigen receptor targeting the CD84 protein. It is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), and is currently administered only to patients enrolled in the Phase I/IIa clinical trial at Hospital La Fe and Hospital Clínic Barcelona.

Quantifiable outcome

• Strong preclinical efficacy in AML and T-ALL animal models with disease eradication and prolonged survival
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Hospital La Fe / IIS La FecoreStrategic or Co-development Partner · 1 January 2026Health Research Institute affiliated with Hospital La Fe in Valencia. Participating site in Gyala's Phase I/IIa clinical trial with Dr. Pau Montesinos as Principal Investigator and Study Coordinator. Also responsible for GMP manufacturing of GYA01 for patients treated at the site, following AEMPS certification of their Advanced Therapies Unit.
• Hospital Clínic Barcelona / IDIBAPScoreStrategic or Co-development Partner · 1 January 2020Founding institutions of Gyala Therapeutics as a spin-off. Hospital Clínic Barcelona is a participating site in the Phase I/IIa clinical trial with Dr. Jordi Esteve as Principal Investigator. Institutions have extensive expertise in academic CAR-T development including ARI-0001 and ARI-0002h. Dr. Manel Juan serves as scientific founder and observer on the Board.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Adaptimmune: Develops engineered T-cell therapies including TCR-T and CAR-T programs for hematologic malignancies and solid tumors. Comparable cell therapy focus with approved Tecelra for synovial sarcoma.
• Autolus Therapeutics: Clinical-stage CAR-T company developing obecabtagene autoleucel for B-ALL and other hematologic programs. Comparable stage and modality with focused hematologic CAR-T pipeline.
• Cellectis: Clinical-stage biotech developing allogeneic (off-the-shelf) CAR-T therapies including UCART123 for AML. Directly competes with Gyala in the AML CAR-T space using a different modality (gene-edited allogeneic vs autologous).
• Precision Biosciences: Developing allogeneic CAR-T therapies using ARCUS gene editing, including candidates targeting AML. Comparable stage and CAR-T focus in hematologic cancers, though using a different gene-editing platform.
• Caribou Biosciences: Clinical-stage allogeneic CAR-T developer (CB-010, CB-011) for hematologic malignancies. Comparable biotech stage and CAR-T modality targeting similar indications with off-the-shelf approach.

Emerging players

• Beam Therapeutics: Base-editing platform company with CAR-T and engineered cell therapy programs for hematologic cancers. Comparable early-clinical gene-modified cell therapy approach relevant to Gyala's autologous CAR-T work.
• Fate Therapeutics: iPSC-derived NK and T-cell therapy developer with multiple hematologic cancer programs. Comparable modality-overlap as a cell therapy platform company pursuing AML and other hematologic indications.
• Century Therapeutics: iPSC-derived allogeneic CAR-T and CAR-NK developer with programs in hematologic malignancies including AML. Emerging competitor with similar clinical-stage profile to Gyala.

Broad incumbents

• Allogene Therapeutics: Leading allogeneic CAR-T platform company with multiple clinical programs in hematologic malignancies including AML. Larger, well-capitalized incumbent whose off-the-shelf approach directly competes with Gyala's autologous CD84 program.
• CRISPR Therapeutics: Gene-editing leader with allogeneic CAR-T programs (CTX112) in B-cell malignancies and emerging hematology pipeline. Larger, more advanced peer whose platform could extend into AML/T-ALL.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInes.linkedin.com/company/gyala-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gyala Therapeutics